Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease

Neurobiology of Disease

Volumn 45, Issue 3, 2012, Pages 1051-1067

  Goldberg, Natalie R S ^a   Fields, Victoria ^b   Pflibsen, Lacey ^a   Salvatore, Michael F ^b   Meshul, Charles K ^a,c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Dopamine; MPTP; Social enrichment; Striatum; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DOPAMINE TRANSPORTER; LEVODOPA; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN CELL; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; DORSOLATERAL CAUDATE PUTAMEN; DRUG EFFICACY; DRUG TARGETING; ENVIRONMENTAL ENRICHMENT; FEMALE; IMMUNOREACTIVITY; MALE; MOTOR DYSFUNCTION; MOUSE; NERVE LESION; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PUTAMEN; REARING; SOCIAL ENRICHMENT; SUBSTANTIA NIGRA PARS COMPACTA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; CELL COUNT; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENT; GENE EXPRESSION REGULATION; LEVODOPA; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84856574257     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.12.024     Document Type: Article

References (122)

1. Antzoulatos E., et al. Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease. Pharmacol. Biochem. Behav. 2010, 95:466-472.
2. Baquet Z.C., et al. A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience 2009, 161:1082-1090.
3. Bardo M.T., et al. Effect of differential rearing environments on morphine-induced behaviors, opioid receptors and dopamine synthesis. Neuropharmacology 1997, 36:251-259.
4. Batchelor P.E., et al. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci. 1999, 19:1708-1716.
5. Batchelor P.E., et al. Macrophages and microglia produce local trophic gradients that stimulate axonal sprouting toward but not beyond the wound edge. Mol. Cell. Neurosci. 2002, 21:436-453.
6. Benes F.M., Lange N. Two-dimensional versus three-dimensional cell counting: a practical perspective. Trends Neurosci. 2001, 24:11-17.
7. Bernheimer H., et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
8. Berry, A., et al., 2011. Social deprivation stress is a triggering factor for the emergence of anxiety- and depression-like behaviours and leads to reduced brain BDNF levels in C57BL/6J mice. Psychoneuroendocrinology. doi:. doi:10.1016/j.physletb.2003.10.071.
9. Bezard E., et al. Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors. J. Neurosci. 2003, 23:10999-11007.
10. Bezard E., et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 2001, 21:6853-6861.
11. Bezard E., et al. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 1999, 155:268-273.
12. Bianchine J.R. Drug therapy of parkinsonism. N. Engl. J. Med. 1976, 295:814-818.
13. Blume S.R., et al. Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism. Exp. Neurol. 2009, 219:208-211.
14. Bowling S.L., Bardo M.T. Locomotor and rewarding effects of amphetamine in enriched, social, and isolate reared rats. Pharmacol. Biochem. Behav. 1994, 48:459-464.
15. Branchi I., et al. Early social enrichment shapes social behavior and nerve growth factor and brain-derived neurotrophic factor levels in the adult mouse brain. Biol. Psychiatry 2006, 60:690-696.
16. Cambon K., et al. Aggressive behavior during social interaction in mice is controlled by the modulation of tyrosine hydroxylase expression in the prefrontal cortex. Neuroscience 2010, 171:840-851.
17. Carta A.R., Frau L., Pisanu A., Wardas J., Spiga S., Carboni E. Rosiglitazone decreases preoxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience 2011, 194:250-261.
18. Chu P.W., et al. Differential regional effects of methamphetamine on dopamine transport. Eur. J. Pharmacol. 2008, 590:105-110.
19. Ciliax B.J., et al. The dopamine transporter: immunochemical characterization and localization in brain. J. Neurosci. 1995, 15:1714-1723.
20. Cirulli F., et al. Early life influences on emotional reactivity: evidence that social enrichment has greater effects than handling on anxiety-like behaviors, neuroendocrine responses to stress and central BDNF levels. Neurosci. Biobehav. Rev. 2010, 34:808-820.
21. Clarke P.G. How inaccurate is the Abercrombie correction factor for cell counts?. Trends Neurosci. 1992, 15:211-212.
22. Cohen A.D., et al. Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. J. Neurochem. 2003, 85:299-305.
23. Cooper J.A., et al. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991, 114(Pt 5):2095-2122.
24. Criscuolo, C., et al., 2011. The LRRK2 R1441C mutation is more frequent than G2019S in Parkinson's disease patients from Southern Italy. Mov. Disord. 26 (9), 1733-1736.
25. Cvejic V., et al. Monoamines and related enzymes in cerebral cortex and basal ganglia following transient ischemia in gerbils. Acta Neuropathol. 1980, 51:71-77.
26. Dluzen D.E., Kreutzberg J.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) disrupts social memory/recognition processes in the male mouse. Brain Res. 1993, 609:98-102.
27. Doty R.L., et al. Olfactory testing as an aid in the diagnosis of Parkinson's disease: development of optimal discrimination criteria. Neurodegeneration 1995, 4:93-97.
28. Duty, S., Jenner, P., 2011. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 164 (4), 1357-1391.
29. Eison M.S., et al. Opposed effects of locus coeruleus and substantia nigra lesions on social behavior in rat colonies. Pharmacol. Biochem. Behav. 1977, 7:87-90.
30. Elliott B.M., Grunberg N.E. Effects of social and physical enrichment on open field activity differ in male and female Sprague-Dawley rats. Behav. Brain Res. 2005, 165:187-196.
31. Elsworth J.D., et al. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 2000, 95:399-408.
32. Faherty C.J., et al. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism. Brain Res. Mol. Brain Res. 2005, 134:170-179.
33. Ferguson M.C., et al. 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Neuropharmacology 2010, 59:31-36.
34. Finkelstein D.I., et al. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 2000, 97:99-112.
35. Fisher B.E., et al. Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. J. Neurosci. Res. 2004, 77:378-390.
36. Fleming S.M., et al. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp. Neurol. 2004, 187:418-429.
37. Fowler C.D., et al. The effects of social environment on adult neurogenesis in the female prairie vole. J. Neurobiol. 2002, 51:115-128.
38. Frost J.J., et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann. Neurol. 1993, 34:423-431.
39. Gabriel A.F., et al. Preoperative housing in an enriched environment significantly reduces the duration of post-operative pain in a rat model of knee inflammation. Neurosci. Lett. 2010, 469:219-223.
40. Gabriel A.F., et al. Enriched environment and the recovery from inflammatory pain: social versus physical aspects and their interaction. Behav. Brain Res. 2010, 208:90-95.
41. Gainetdinov R.R., et al. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 1997, 69:1322-1325.
42. Gao H.M., et al. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 2002, 81:1285-1297.
43. Garcia Navia J.T., et al. Regional-specific regulation of BDNF and trkB correlates with nigral dopaminergic cell sprouting following unilateral nigrostriatal axotomy. J. Neurosci. Res. 2008, 86:2016-2027.
44. Garris P.A., et al. Real-time measurement of electrically evoked extracellular dopamine in the striatum of freely moving rats. J. Neurochem. 1997, 68:152-161.
45. Garris P.A., et al. Dopamine release and uptake rates both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals. Brain Res. 1997, 753:225-234.
46. Gheusi G., et al. A niche for adult neurogenesis in social behavior. Behav. Brain Res. 2009, 200:315-322.
47. Globus M.Y., et al. Role of dopamine in ischemic striatal injury: metabolic evidence. Neurology 1987, 37:1712-1719.
48. Goldberg N.R., et al. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 2011, 180:256-271.
49. Goldberg N.R., et al. Enriched environment promotes similar neuronal and behavioral recovery in a young and aged mouse model of Parkinson's disease. Neuroscience 2011, 172:443-452.
50. Goldberg, N. R., et al., 2011c. Profiling changes in gait dynamics resulting from progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal lesioning. J Neurosci Res. 89, 1698-1706.
51. Goldberg N.R., Meshul C.K. Effect of intermittent washout periods on progressive lesioning of the nigrostriatal pathway with 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuroscience 2011, 182:203-207.
52. Gomez-Pinilla F., et al. Physical exercise induces FGF-2 and its mRNA in the hippocampus. Brain Res. 1997, 764:1-8.
53. Grimbergen Y.A., et al. Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev. Neurother. 2009, 9:279-290.
54. Halliday G., et al. Milestones in Parkinson's disease-clinical and pathologic features. Mov. Disord. 2011, 26:1015-1021.
55. Hawkes C.H., et al. A timeline for Parkinson's disease. Parkinsonism Relat. Disord. 2010, 16:79-84.
56. Hersch S.M., et al. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J. Comp. Neurol. 1997, 388:211-227.
57. Innis R.B., et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:11965-11969.
58. Iravani M.M., et al. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Eur. J. Neurosci. 2005, 21:841-854.
59. Jaber M., et al. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. Eur. J. Neurosci. 1999, 11:3499-3511.
60. Jackson-Lewis V., et al. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4:257-269.
61. Jakowec M.W., et al. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway. J. Neurosci. Res. 2004, 76:539-550.
62. Jakowec M.W., Petzinger G.M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates. Comp. Med. 2004, 54:497-513.
63. Kamens H.M., Crabbe J.C. The parallel rod floor test: a measure of ataxia in mice. Nat. Protoc. 2007, 2:277-281.
64. Kamens H.M., et al. Characterization of the parallel rod floor apparatus to test motor incoordination in mice. Genes Brain Behav. 2005, 4:253-266.
65. Keller C.M., et al. Biphasic dopamine regulation in mesoaccumbens pathway in response to non-contingent binge and escalating methamphetamine regimens in the Wistar rat. Psychopharmacology (Berl) 2011, 215:513-526.
66. Ladinsky H., et al. Cholinergic-dopaminergic interaction in the striatum: the effect of 6-hydroxydopamine or pimozide treatment on the increased striatal acetylcholine levels induced by apomorphine, piribedil and d-amphetamine. Brain Res. 1975, 84:221-226.
67. Lester D.B., et al. Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 2010, 16:137-162.
68. Li L., Tang B.L. Environmental enrichment and neurodegenerative diseases. Biochem. Biophys. Res. Commun. 2005, 334:293-297.
69. Li X., et al. Chronic behavioral testing after focal ischemia in the mouse: functional recovery and the effects of gender. Exp. Neurol. 2004, 187:94-104.
70. Lie D.C., et al. The adult substantia nigra contains progenitor cells with neurogenic potential. J. Neurosci. 2002, 22:6639-6649.
71. Lindvall O., McKay R. Brain repair by cell replacement and regeneration. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:7430-7431.
72. Lu L., et al. Modification of hippocampal neurogenesis and neuroplasticity by social environments. Exp. Neurol. 2003, 183:600-609.
73. Marsden C.D. Parkinson's disease. Lancet 1990, 335:948-952.
74. McGeorge A.J., Faull R.L. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience 1989, 29:503-537.
75. Meredith G.E., Rademacher D.J. MPTP mouse models of Parkinson's disease: an update. J. Parkinson's Dis. 2011, 1:19-33.
76. Meredith G.E., et al. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat. Disord. 2008, 14(Suppl 2):S112-S115.
77. Miller G.W., et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp. Neurol. 1999, 156:138-148.
78. Miller J.A., et al. Low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor-kappaB reporter mice prior to loss of dopaminergic neurons. J. Neurosci. Res. 2011, 89:406-417.
79. Mori F., et al. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra. J. Neuropathol. Exp. Neurol. 2006, 65:808-815.
80. Muangpaisan W., et al. Systematic review of the prevalence and incidence of Parkinson's disease in Asia. J. Epidemiol. 2009, 19:281-293.
81. Muangpaisan W., et al. A systematic review of the worldwide prevalence and incidence of Parkinson's disease. J. Med. Assoc. Thai. 2011, 94:749-755.
82. Muroyama A., et al. Loss of striatal dopaminergic terminals during the early stage in response to MPTP injection in C57BL/6 mice. Neurosci. Res. 2011, 69:352-355.
83. Nomoto M., et al. Increased dopamine turnover in the putamen after MPTP treatment in common marmosets. Brain Res. 1997, 767:235-238.
84. Obeso J.A., et al. Missing pieces in the Parkinson's disease puzzle. Nat. Med. 2010, 16:653-661.
85. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2004, Elsevier Academic Press, Amsterdam; Boston.
86. Petzinger G.M., et al. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins. J. Neurosci. Res. 2006, 83:332-347.
87. Pietropaolo S., et al. Long-term effects of the periadolescent environment on exploratory activity and aggressive behaviour in mice: social versus physical enrichment. Physiol. Behav. 2004, 81:443-453.
88. Pisani A., et al. Targeting striatal cholinergic interneurons in Parkinson's disease: focus on metabotropic glutamate receptors. Neuropharmacology 2003, 45:45-56.
89. Postuma R.B., et al. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006, 66:845-851.
90. Postuma R.B., Montplaisir J. Potential early markers of Parkinson's disease in idiopathic rapid-eye-movement sleep behaviour disorder. Lancet Neurol. 2006, 5:552-553.
91. Potashkin J.A., et al. Limitations of animal models of Parkinson's disease. Parkinsons Dis. 2010, 2011:658083.
92. Prado V.F., et al. Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron 2006, 51:601-612.
93. Prediger R.D., Takahashi R.N. Modulation of short-term social memory in rats by adenosine A1 and A(2A) receptors. Neurosci. Lett. 2005, 376:160-165.
94. Przedborski S. Neuroinflammation and Parkinson's disease. Handb. Clin. Neurol. 2007, 83:535-551.
95. Ricaurte G.A., McCann U.D. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann. N. Y. Acad. Sci. 1992, 648:371-382.
96. Rommelfanger K.S., et al. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13804-13809.
97. Salahpour A., et al. Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4405-4410.
98. Salvatore M.F., et al. Aging reveals a role for nigral tyrosine hydroxylase ser31 phosphorylation in locomotor activity generation. PLoS One 2009, 4:e8466.
99. Santiago M., et al. Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine. Eur. J. Pharmacol. 1995, 280:251-256.
100. Schneider J.S. Effects of age on GM1 ganglioside-induced recovery of concentrations of dopamine in the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. Neuropharmacology 1992, 31:185-192.
101. Schneider J.S., et al. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science 1992, 256:843-846.
102. Schutz B., et al. Vesicular amine transporter expression and isoform selection in developing brain, peripheral nervous system and gut. Brain Res. Dev. Brain Res. 1998, 106:181-204.
103. Seidl S.E., Potashkin J.A. The promise of neuroprotective agents in Parkinson's disease. Front. Neurol. 2011, 2:68. 10.3389/fneur.2011.00068.
104. Shan X., et al. Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice. Stem Cells 2006, 24:1280-1287.
105. Smeyne R.J., Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res. Mol. Brain Res. 2005, 134:57-66.
106. Smith B.A., et al. Effects of treadmill exercise on behavioral recovery and neural changes in the substantia nigra and striatum of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse. Brain Res. 2011, 1386:70-80.
107. Smolen A.J., et al. Neuron numbers in the superior cervical sympathetic ganglion of the rat: a critical comparison of methods for cell counting. J. Neurocytol. 1983, 12:739-750.
108. Song D.D., Haber S.N. Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting. J. Neurosci. 2000, 20:5102-5114.
109. Steiner B., et al. Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease. Exp. Neurol. 2006, 199:291-300.
110. Sundstrom E., et al. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res. 1987, 405:26-38.
111. Tadaiesky M.T., et al. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
112. Thiffault C., et al. Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res. 2000, 885:283-288.
113. Tillerson J.L., Miller G.W. Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism. J. Neurosci. Methods 2003, 123:189-200.
114. von Campenhausen S., et al. Prevalence and incidence of Parkinson's disease in Europe. Eur. Neuropsychopharmacol. 2005, 15:473-490.
115. Wang Y.C., et al. Effects of single and group housing conditions and alterations in social and physical contexts on amphetamine-induced behavioral sensitization in rats. Neurosci. Lett. 2010, 486:34-37.
116. Wilson J.M., Kish S.J. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J. Neurosci. 1996, 16:3507-3510.
117. Wong K.K., et al. Olfactory loss and nigrostriatal dopaminergic denervation in the elderly. Neurosci. Lett. 2010, 484:163-167.
118. Wooten G.F., et al. Are men at greater risk for Parkinson's disease than women?. J. Neurol. Neurosurg. Psychiatry 2004, 75:637-639.
119. Wu S.Y., et al. Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway. Brain Behav. Immun. 2011, 25:135-146.
120. Zhao M., et al. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:7925-7930.
121. Zigmond M.J., et al. Partial damage to nigrostriatal bundle: compensatory changes and the action of L-dopa. J. Neural Transm. Suppl. 1990, 29:217-232.
122. Zigmond M.J., Stricker E.M. Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. Int. Rev. Neurobiol. 1989, 31:1-79.